First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

Core Viewpoint - CollPlant Biotechnologies has announced the development of the first fully humanized 3D bioprinted skin model using its proprietary plant-derived recombinant human collagen (rhCollagen), which offers a sustainable alternative to animal testing for preclinical research and has broad applications in cosmetic and pharmaceutical testing, disease modeling, and drug development [1][7]. Group 1: Technology and Innovation - The 3D bioprinted skin model integrates CollPlant's rhCollagen-based bioinks with essential human skin cell types, enabling the evaluation of drug delivery in a non-animal model [2][7]. - The use of plant-derived rhCollagen allows for high-throughput production of personalized human skin models, which can be applied in regenerative medicine and other medical fields [2][3]. Group 2: Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing 3D bioprinting technologies for tissue repair and medical aesthetics, with products based on its proprietary rhCollagen [4]. - The company has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers, indicating its strategic partnerships in the market [5]. Group 3: Market Implications - The innovative skin model represents a significant advancement in reducing animal testing and enhancing the ethical standards of preclinical research, which could lead to broader acceptance and application in the cosmetic and pharmaceutical industries [1][7]. - The results from Mayo Clinic's research validate the potential of rhCollagen-based bioinks for various applications, including in vitro 3D models and regenerative medicine [3].